Hospital
Steward Holy Family Hospital, INC.
Steward Holy Family Hospital, INC. was paid $70.80M by Medicaid between Jan 2018 and Nov 2024, across 381 billing codes. Its largest line is 99283, emergency room visit (moderate) — 14% of everything it billed.
33Billing provider infoSTEWARD HOLY FAMILY HOSPITAL, INC.
METHUEN, MA 01844
METHUEN, MA 01844
33aNPI1033421664assigned 07/12/2010
33bProvider typeGeneral Acute Care Hospital
28Total paid$70.80M
24GClaims1,898,180
24DCodes billed381
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Massachusetts
Rank by total paid#20 of 66
Median peer was paid$29.11M
This provider vs. median2.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RENNA, JAMES controls 11+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 349,108 | $12.63M | |
| 2019 | 326,002 | $10.39M | |
| 2020 | 243,631 | $7.80M | |
| 2021 | 289,704 | $9.92M | |
| 2022 | 287,106 | $9.98M | |
| 2023 | 243,054 | $10.92M | |
| 2024incomplete | 159,575 | $9.15M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 79,898 | 73,716 | $9.66M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 68,470 | 63,185 | $7.94M |
| 96361 | Intravenous infusion, hydration; each additional hour | 10% | 28,248 | 24,988 | $7.09M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.4% | 54,885 | 49,291 | $6.65M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.0% | 25,935 | 23,322 | $3.52M |
| 59025 | Fetal non-stress test | 3.6% | 13,119 | 6,506 | $2.57M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.1% | 16,383 | 15,374 | $2.20M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 2.5% | 13,166 | 13,070 | $1.76M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.3% | 14,477 | 14,001 | $1.62M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.3% | 13,359 | 12,638 | $1.60M |
| S9485 | Crisis intervention mental health services, per diem | 2.2% | 2,483 | 2,310 | $1.59M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 2.2% | 13,414 | 11,747 | $1.57M |
369 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 14,066 | $1.24M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.7% | 8,489 | $1.19M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 8,891 | $758K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.0% | 7,196 | $730K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 5,958 | $680K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 4,572 | $633K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 15,278 | $591K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,315 | $584K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 20,891 | $574K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 8,930 | $559K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 12,781 | $502K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,387 | $476K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,754 | $430K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 4,460 | $407K |
| 92587 | <1% | 3,744 | $399K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 109,736 | $392K |
| 93971 | <1% | 2,492 | $371K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,882 | $367K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,286 | $320K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 11,508 | $315K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 5,061 | $302K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,586 | $275K |
| 93975 | <1% | 3,064 | $264K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,675 | $260K |
| ATP14 | <1% | 26,694 | $244K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,399 | $224K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 5,071 | $218K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,249 | $215K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 790 | $213K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 11,029 | $203K |
| 76830 | Ultrasound, transvaginal | <1% | 2,514 | $201K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 24,089 | $196K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 9,159 | $196K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 32,315 | $194K |
| G0378 | Hospital observation service, per hour | <1% | 11,225 | $192K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,398 | $192K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 250 | $190K |
| 64493 | <1% | 449 | $180K | |
| 12001 | <1% | 952 | $180K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,700 | $173K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,398 | $168K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 12,656 | $165K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 6,493 | $161K |
| 84484 | <1% | 38,803 | $160K | |
| 76642 | <1% | 1,550 | $157K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 8,755 | $156K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 33,058 | $155K |
| 87631 | <1% | 2,171 | $148K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 34,736 | $148K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 594 | $141K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,794 | $129K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 855 | $129K |
| 76801 | <1% | 3,059 | $123K | |
| 97597 | <1% | 1,832 | $120K | |
| 97803 | <1% | 1,512 | $114K | |
| 84702 | <1% | 13,872 | $113K | |
| 93017 | <1% | 1,615 | $111K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 481 | $109K |
| 93976 | <1% | 1,291 | $108K | |
| ATP08 | <1% | 15,426 | $108K | |
| 81025 | <1% | 25,357 | $99K | |
| 99219 | <1% | 2,003 | $95K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,348 | $94K |
| 97161 | <1% | 2,739 | $92K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 623 | $90K |
| 76775 | <1% | 825 | $90K | |
| 83690 | <1% | 25,015 | $87K | |
| 76536 | <1% | 815 | $84K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 19,360 | $80K |
| 80053 | Comprehensive metabolic panel | <1% | 60,473 | $78K |
| 19318 | <1% | 12 | $78K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 179 | $75K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,957 | $73K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 110 | $72K |
| 97802 | <1% | 928 | $72K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 7,473 | $70K |
| 83880 | <1% | 5,851 | $68K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 39,143 | $68K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,679 | $68K |
| 81001 | <1% | 42,744 | $67K | |
| 71250 | <1% | 1,104 | $66K | |
| 12011 | <1% | 276 | $65K | |
| 99173 | <1% | 3,235 | $59K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 49,758 | $59K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,400 | $57K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,385 | $56K |
| ATP15 | <1% | 6,322 | $55K | |
| 20610 | <1% | 561 | $54K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15,170 | $53K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 687 | $52K |
| 20553 | <1% | 333 | $49K | |
| 90715 | <1% | 3,711 | $47K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 904 | $45K |
| 72141 | <1% | 253 | $44K | |
| 64494 | <1% | 411 | $43K | |
| 72100 | <1% | 3,401 | $43K | |
| 70498 | <1% | 418 | $41K | |
| 97010 | <1% | 950 | $40K | |
| 84600 | <1% | 5,198 | $40K | |
| 93970 | <1% | 103 | $38K | |
| 77080 | <1% | 667 | $37K | |
| 71045 | Radiologic examination, chest; single view | <1% | 14,854 | $36K |
| 84703 | <1% | 8,634 | $35K | |
| 90733 | <1% | 700 | $35K | |
| 85379 | <1% | 6,640 | $35K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 444 | $35K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,088 | $34K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 3,973 | $34K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 121 | $34K |
| 86850 | <1% | 6,447 | $33K | |
| 12002 | <1% | 179 | $33K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 25,577 | $33K |
| 87040 | <1% | 7,327 | $31K | |
| 81003 | <1% | 26,835 | $30K | |
| 83735 | <1% | 10,118 | $30K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,558 | $30K |
| 73562 | <1% | 3,595 | $29K | |
| 76770 | <1% | 206 | $28K | |
| 83605 | <1% | 5,828 | $26K | |
| 87807 | <1% | 2,647 | $25K | |
| 64495 | <1% | 151 | $25K | |
| 87081 | <1% | 5,392 | $25K | |
| 80050 | General health panel | <1% | 1,858 | $24K |
| 87186 | <1% | 5,561 | $24K | |
| 85610 | <1% | 13,046 | $22K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 223 | $22K |
| 76870 | <1% | 282 | $21K | |
| 73030 | <1% | 3,277 | $20K | |
| 86900 | <1% | 7,744 | $20K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,586 | $20K |
| 73130 | <1% | 3,200 | $19K | |
| 73630 | <1% | 3,741 | $19K | |
| 87077 | <1% | 5,205 | $19K | |
| 74018 | <1% | 1,713 | $19K | |
| 82947 | <1% | 20,892 | $19K | |
| 17250 | <1% | 77 | $18K | |
| 87070 | <1% | 4,011 | $18K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 712 | $17K |
| 10060 | <1% | 103 | $17K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 15,207 | $17K |
| 85027 | <1% | 5,608 | $17K | |
| 73610 | <1% | 4,170 | $17K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 44,954 | $17K |
| 92557 | <1% | 579 | $17K | |
| 90621 | <1% | 245 | $16K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 25 | $16K |
| 70486 | <1% | 358 | $16K | |
| 82728 | <1% | 2,099 | $16K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,715 | $16K |
| 82805 | <1% | 578 | $16K | |
| 87147 | <1% | 2,870 | $15K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 112 | $15K |
| 86901 | <1% | 7,752 | $14K | |
| 85730 | <1% | 5,135 | $14K | |
| 77065 | Tomosynthesis, mammo | <1% | 292 | $14K |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 40 | $13K |
| 62323 | <1% | 68 | $13K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 384 | $12K |
| 82607 | <1% | 1,396 | $12K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 137 | $12K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 27,553 | $12K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 66 | $11K |
| 70496 | <1% | 495 | $11K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 23,592 | $11K |
| 92567 | <1% | 1,292 | $11K | |
| 84466 | <1% | 1,382 | $10K | |
| 92556 | <1% | 156 | $10K | |
| 73110 | <1% | 2,010 | $10K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,139 | $10K |
| 70491 | <1% | 81 | $10K | |
| 97035 | <1% | 228 | $9K | |
| 88304 | <1% | 1,718 | $9K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 12,766 | $9K |
| 82746 | <1% | 962 | $9K | |
| 73502 | <1% | 1,174 | $9K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 16,486 | $8K |
| 87641 | <1% | 365 | $8K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,063 | $8K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 12,204 | $8K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 430 | $8K |
| 77336 | <1% | 63 | $8K | |
| 72131 | <1% | 319 | $8K | |
| 88342 | <1% | 1,811 | $8K | |
| 77066 | Tomosynthesis, mammo | <1% | 221 | $8K |
| J2704 | Injection, propofol, 10 mg | <1% | 14,458 | $8K |
| 80076 | <1% | 13,745 | $7K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 141 | $7K |
| 85007 | <1% | 4,198 | $7K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,359 | $7K |
| 87428 | <1% | 111 | $7K | |
| 36430 | <1% | 34 | $7K | |
| ATP02 | <1% | 2,270 | $6K | |
| 99381 | <1% | 90 | $6K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 55 | $6K |
| 87205 | <1% | 3,161 | $6K | |
| 76813 | <1% | 89 | $6K | |
| 83540 | <1% | 1,586 | $6K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 317 | $6K |
| 72040 | <1% | 301 | $6K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 12 | $6K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 7,647 | $6K |
| 97116 | <1% | 232 | $6K | |
| ATP03 | <1% | 1,644 | $6K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 152 | $6K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 9,546 | $5K |
| 76857 | <1% | 71 | $5K | |
| 94060 | <1% | 60 | $5K | |
| 87486 | <1% | 247 | $5K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,467 | $4K |
| 64483 | <1% | 12 | $4K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 4,084 | $4K |
| 77062 | <1% | 40 | $4K | |
| 87808 | <1% | 593 | $4K | |
| 85652 | <1% | 2,972 | $4K | |
| 84425 | <1% | 265 | $4K | |
| 80179 | <1% | 1,142 | $4K | |
| 73140 | <1% | 451 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,634 | $3K |
| 76000 | <1% | 305 | $3K | |
| 74246 | <1% | 21 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,948 | $3K |
| 80061 | Lipid panel | <1% | 4,354 | $3K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,252 | $3K |
| 81513 | <1% | 32 | $3K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 130 | $3K |
| 82565 | <1% | 3,536 | $3K | |
| 95816 | <1% | 13 | $3K | |
| ATP17 | <1% | 372 | $3K | |
| 72070 | <1% | 49 | $2K | |
| 83921 | <1% | 169 | $2K | |
| 86140 | <1% | 834 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,202 | $2K |
| 73080 | <1% | 562 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 9,726 | $2K |
| J3490 | Unclassified drugs | <1% | 70 | $2K |
| 82570 | <1% | 789 | $2K | |
| 99253 | <1% | 13 | $2K | |
| 87075 | <1% | 504 | $2K | |
| 83655 | <1% | 181 | $2K | |
| 84112 | <1% | 26 | $2K | |
| 73221 | <1% | 13 | $2K | |
| 87640 | <1% | 201 | $2K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 13 | $2K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,319 | $2K |
| 87088 | <1% | 472 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,615 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,509 | $1K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,787 | $1K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 583 | $1K |
| 90474 | <1% | 5,592 | $1K | |
| 97162 | <1% | 27 | $1K | |
| 80143 | <1% | 1,426 | $1K | |
| 90837 | Psychotherapy session, about an hour | <1% | 13 | $1K |
| 94729 | <1% | 59 | $1K | |
| 84520 | <1% | 3,347 | $995.64 | |
| 84590 | <1% | 125 | $942.36 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,450 | $941.44 |
| 71271 | <1% | 17 | $896.31 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 508 | $893.35 |
| 87899 | <1% | 123 | $874.19 | |
| 87481 | <1% | 47 | $839.89 | |
| 86580 | <1% | 91 | $740.70 | |
| 83550 | <1% | 154 | $694.22 | |
| 90686 | <1% | 90 | $684.68 | |
| 82272 | <1% | 333 | $620.80 | |
| 83918 | <1% | 68 | $610.56 | |
| 96376 | <1% | 3,600 | $609.76 | |
| 93041 | <1% | 390 | $595.87 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 13 | $573.32 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 159 | $564.86 |
| 84439 | <1% | 105 | $497.09 | |
| 83090 | <1% | 41 | $486.75 | |
| 99383 | <1% | 14 | $471.80 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 813 | $467.41 |
| 84445 | <1% | 13 | $463.90 | |
| 80164 | <1% | 76 | $461.34 | |
| 77002 | <1% | 30 | $447.15 | |
| 83970 | <1% | 13 | $436.92 | |
| 73590 | <1% | 69 | $415.98 | |
| 88142 | <1% | 28 | $406.56 | |
| ATP09 | <1% | 85 | $394.24 | |
| 84146 | <1% | 28 | $382.36 | |
| 82550 | <1% | 980 | $353.70 | |
| 82533 | <1% | 27 | $333.61 | |
| 82150 | <1% | 85 | $327.32 | |
| 73521 | <1% | 12 | $298.45 | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 603 | $280.54 |
| 86703 | <1% | 28 | $262.50 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 91 | $261.22 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,560 | $240.47 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 172 | $221.69 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 14 | $219.32 |
| 72072 | <1% | 12 | $217.23 | |
| 87480 | <1% | 14 | $212.16 | |
| 82248 | <1% | 375 | $197.09 | |
| 82247 | <1% | 208 | $184.41 | |
| 86923 | <1% | 15 | $183.42 | |
| 83615 | <1% | 317 | $180.80 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,350 | $175.58 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 554 | $160.07 |
| 73090 | <1% | 26 | $157.48 | |
| 80320 | <1% | 868 | $156.91 | |
| 90658 | <1% | 6,040 | $155.25 | |
| 84134 | <1% | 15 | $154.44 | |
| 84460 | <1% | 298 | $148.09 | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 16 | $147.83 |
| 84450 | <1% | 226 | $144.62 | |
| 86618 | <1% | 14 | $132.74 | |
| 85384 | <1% | 16 | $128.55 | |
| 87046 | <1% | 15 | $126.62 | |
| 87045 | <1% | 15 | $107.14 | |
| 81002 | <1% | 42 | $105.60 | |
| 83525 | <1% | 13 | $104.30 | |
| ATP06 | <1% | 14 | $98.28 | |
| 84550 | <1% | 275 | $97.93 | |
| 84153 | <1% | 12 | $97.32 | |
| 86592 | <1% | 29 | $93.21 | |
| 84156 | <1% | 33 | $92.15 | |
| 85651 | <1% | 33 | $80.30 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 5,695 | $77.24 |
| 88311 | <1% | 12 | $72.75 | |
| 82043 | <1% | 27 | $68.64 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 754 | $62.27 |
| 80177 | <1% | 17 | $54.68 | |
| 86308 | <1% | 13 | $53.40 | |
| 82010 | <1% | 15 | $50.47 | |
| 90734 | <1% | 1,344 | $42.87 | |
| 84100 | <1% | 159 | $42.08 | |
| 90707 | <1% | 2,066 | $31.11 | |
| 90716 | <1% | 1,992 | $22.02 | |
| 73560 | <1% | 32 | $19.73 | |
| 90685 | <1% | 3,899 | $13.26 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,642 | $9.11 |
| 99406 | <1% | 142 | $6.92 | |
| 90634 | 0% | 684 | $0.00 | |
| 80329 | 0% | 347 | $0.00 | |
| 90680 | 0% | 5,703 | $0.00 | |
| 90657 | 0% | 2,601 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 501 | $0.00 |
| 94760 | 0% | 83 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 384 | $0.00 |
| 90698 | 0% | 1,531 | $0.00 | |
| C1769 | Guide wire | 0% | 150 | $0.00 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 0% | 47 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 48 | $0.00 |
| 90647 | 0% | 84 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 29 | $0.00 |
| 90744 | 0% | 704 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 20 | $0.00 |
| Q3014 | Telehealth originating site facility fee | 0% | 35 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 44 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 63 | $0.00 |
| 90723 | 0% | 71 | $0.00 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 17 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 15 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 67 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 627 | $0.00 |
| 90649 | 0% | 2,408 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 288 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 233 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 98 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 462 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 422 | $0.00 |
| 90710 | 0% | 229 | $0.00 | |
| A4649 | Surgical supply; miscellaneous | 0% | 224 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 105 | $0.00 |
| C1765 | Adhesion barrier | 0% | 41 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 44 | $0.00 |
| 84145 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRENNA, JAMES (CHIEF FINANCIAL OFFICER)
Parent organizationSTEWARD HEALTH CARE SYSTEM LLC
| Provider | Location | Paid |
|---|---|---|
| Steward Good Samaritan Medical Center, INC. | Brockton, MA | $64.10M |
| Steward Carney Hospital, INC. | Dorchester Center, MA | $56.76M |
| Steward ST. Elizabeth's Medical Center of Boston, INC. | Boston, MA | $32.53M |
| Steward Norwood Hospital, INC. | Norwood, MA | $8.47M |
| Steward ST. Elizabeth's Medical Center of Boston, INC. | Boston, MA | $1.90M |
| Steward Holy Family Hospital, INC. | Methuen, MA | $1.06M |
| New England Sinai Hospital, a Steward Family Hospital, INC. | Stoughton, MA | $136K |
| Steward Carney Hospital, INC. | Dorchester Center, MA | $52K |
| Steward Good Samaritan Medical Center, INC. | Brockton, MA | $29K |
| Morton Hospital, a Steward Family Hospital, INC. | Taunton, MA | $11K |
| Steward ST. Anne's Hospital Corporation | Fall River, MA | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.